Working… Menu

Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01461265
Recruitment Status : Completed
First Posted : October 28, 2011
Last Update Posted : July 15, 2015
Information provided by (Responsible Party):
Galil Medical, a wholly owned indirect subsidiary of Boston Scientific

Brief Summary:
This study will evaluate the safety and efficacy of cryoablation therapy for relief of pain associated with metastatic bone tumors.

Condition or disease Intervention/treatment Phase
Pain Neoplasm Metastasis Procedure: Cryoablation Phase 1

Detailed Description:

Patients with painful bone metastases who meet the eligibility criteria and who have been determined to be an appropriate candidate for cryoablation therapy will be offered enrollment into the study. Cryoablation is the process of destroying tissue by the application of extremely cold temperatures. Galil Medical Cryoablation Systems are used as a surgical tool in the fields of general surgery, dermatology (skin), neurology (nerves), chest surgery (including lung), Ears-Nose-Throat (ENT), gynecology, oncology (cancer), proctology (colon/rectal) and urology (kidney).

Patients agreeing to participate will read and sign an informed consent form and thus become subjects in the study. Treatment will be performed using a Galil Medical cryoablation system and Galil Medical cryoablation needles. Subjects will be followed for up to 24 weeks (6 months) for palliation of pain, quality of life and analgesic usage. Baseline and follow-up data will be collected for each subject via a web-based electronic data collection tool.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 29 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Cryoablation for the Palliation of Painful Bone Metastases
Study Start Date : November 2011
Actual Primary Completion Date : April 2015
Actual Study Completion Date : April 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Palliative Care

Arm Intervention/treatment
All subjects will have cryoablation on one or two painful metastatic bone tumors.
Procedure: Cryoablation
For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
Other Names:
  • Cryotherapy
  • Cryosurgery
  • Visual-ICE Cryoablation System
  • SeedNet Cryoablation System
  • PresIce Cryoablation System
  • IceRod Cryoablation Needle
  • IceRod PLUS Cryoablation Needle
  • IceEDGE 2.4 Cryoablation Needle
  • IceSeed Cryoablation Needle
  • IceSphere Cryoablation Needle

Primary Outcome Measures :
  1. Difference in worst pain scores [ Time Frame: 24 weeks post-cryoablation ]
    The endpoint for this study will be measured as follows: assessment of the effectiveness of cryoablation associated with palliation of pain in subjects with metastatic bone cancer by measuring the average difference of pre- and posttreatment worst pain in 24 hours from baseline to 24 hour, 1, 4, 12, and 24 week follow-up intervals as measured on the numeric 0 to 10 Brief Pain Inventory (BPI) scale.

Secondary Outcome Measures :
  1. Cryoablation retreatments [ Time Frame: 24 weeks post-cryoablation ]
    If the first cryoablation procedure effectively relieves pain but the relief wears off over time and the pain becomes unbearable, a second procedure may be performed. The number of repeat cryoablation treatments will be recorded.

  2. Additional surgical treatments other than cryoablation [ Time Frame: 24 weeks post-cryoablation ]
    If pain is not effectively relieved by the cryoablation, other surgical treatments may be performed. The number of these treatments will be recorded.

  3. Reduced analgesic usage [ Time Frame: 24 weeks post-cryoablation ]
    The number of subjects (percentage) who are able to reduce analgesic medications from baseline to 24 hours, 1, 4, 12, and 24 weeks after cryoablation will be recorded.

  4. Time to maximal palliation of pain after cryoablation [ Time Frame: 24 weeks post-cryoablation ]
    The difference in pain scores will be assessed from baseline to follow-up intervals after cryoablation will be analyzed. The interval indicating the most relief from pain will be compared across subjects.

  5. Subject satisfaction with the amount palliation of pain obtained from cryoablation [ Time Frame: 24 weeks post-cryoablation ]
    Subject satisfaction will be compared at baseline to follow-up intervals.

  6. Number of adverse events [ Time Frame: 30 days post-cryoablation ]
    The safety endpoint for this study is to assess the incidence and severity of intra-operative events, post operative adverse events, serious adverse events and unanticipated adverse device effects related to the cryoablation procedure.

  7. Difference in average pain scores [ Time Frame: 24 weeks post-cryoablation ]
    Difference in average pain scores from baseline to 24 hours, 1, 4, 12, and 24 weeks after cryoablation as measured on the numeric 0 to 10 BPI scale

  8. Time to recurrence of worst pain [ Time Frame: 24 weks post-cryoablation ]
    Time to recurrence of worst pain at or above baseline; worst pain score in the 24 week follow-up period as measured on the numeric 0 to 10 BPI scale

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • Metastatic bone disease with metastatic disease previously confirmed by prior biopsy; or Metastatic bone disease previously confirmed on imaging [e.g. computed tomography (CT) or magnetic resonance imaging (MRI)] with known (biopsied) primary disease (primary bone cancer is excluded)
  • Current analgesic therapies have failed OR the subject is experiencing intolerable side effects
  • Unremitting pain that resulted in a return visit to the oncologist. The 'worst pain' in the last 24 hours must be reported to be 4 or above on a scale of 0 (no pain) to 10 (pain as bad as subject can imagine) despite pharmaceutical pain management
  • Pain must be from one or two painful metastatic sites in the bone that is amenable to cryoablation with CT or MRI (additional less painful metastatic sites may be present)
  • Pain from the reported one or two metastatic sites must correlate with an identifiable tumor on CT, MRI, or ultrasound (US) imaging
  • Tumors must be suitable for cryoablation
  • Cryoablation should be performed within 14 days of baseline evaluations
  • Stable use of hormonal therapy (no changes within 4 weeks prior to the cryoablation procedure)
  • Stable use of pain medications (no changes within 2 weeks prior to the cryoablation procedure)
  • ECOG (Eastern Cooperative Oncology Group) scale performance status 0-3
  • Life expectancy ≥ 2 months
  • Platelet count >50,000/mm³ within 6 weeks screening
  • INR (International Normalized Ratio) <1.5 within 6 weeks screening
  • No debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal treatment and follow-up
  • If taking antiplatelet or anticoagulation medication, it must be able to be discontinued prior to the procedure for an appropriate amount of time (e.g., aspirin, ibuprofen, low molecular weight heparin preparations)
  • Clinically suitable for cryoablation therapy

Exclusion Criteria:

  • Leukemia, lymphoma, and myeloma
  • Tumor involves a weight-bearing long bone of the lower extremity with the tumor causing > 50% loss of cortical bone
  • Has undergone prior ablation treatment of the index tumor
  • Prior radiation therapy of the index tumor <3 weeks prior to screening
  • Index tumor causing clinical or radiographic evidence of spinal cord or cauda equina compression/effacement
  • Anticipated treatment of the index tumor that would require iceball formation within 1.0 cm of the spinal cord, brain, other critical nerve structure, large abdominal vessel such as the aorta or inferior vena cava, bowel, or bladder
  • Surgery at the tumor site or surgery involving the cryoablation-treated tumor (index tumor)
  • Index tumor involves the skull (treatment of other painful tumors in subjects with skull tumors is not excluded)
  • Patient currently with neutropenia (absolute neutrophil count <1000) within 6 weeks screening
  • Uncontrolled coagulopathy or bleeding disorders
  • Currently pregnant, nursing, or wishing to become pregnant during the study
  • Active, uncontrolled infection
  • Serious medical illness, including any of the following: uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction, cerebrovascular event within 6 months prior to study entry
  • Concurrent participation in other experimental studies that could affect the primary endpoint

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01461265

Layout table for location information
United States, Michigan
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, Texas
University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Canada, British Columbia
University of British Columbia
Vancouver, British Columbia, Canada, V5Z 1L8
University Hospital of Strasbourg
Strasbourg, France, F-67091
Sponsors and Collaborators
Galil Medical, a wholly owned indirect subsidiary of Boston Scientific
Layout table for investigator information
Study Chair: Jerry Matteo, MD Shands Medical Center, Jacksonville, FL
Layout table for additonal information
Responsible Party: Galil Medical, a wholly owned indirect subsidiary of Boston Scientific Identifier: NCT01461265    
Other Study ID Numbers: CUC10-BNE11
First Posted: October 28, 2011    Key Record Dates
Last Update Posted: July 15, 2015
Last Verified: July 2015
Keywords provided by Galil Medical, a wholly owned indirect subsidiary of Boston Scientific:
Painful bone metastases
Bone metastases
Metastatic bone tumors
Metastatic bone pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplasms, Second Primary
Neoplastic Processes
Pathologic Processes